New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
06:33 EDTCYTRCytRx begins Phase 2 clinical trial with aldoxorubicin for Kaposi's sarcoma
CytRx has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposiís sarcoma. The primary objective of preliminary efficacy will be determined through evaluation of the size, number and nodularity of skin lesions, and the company will evaluate the level of aldoxorubicin uptake into lesions. CytRx plans to discuss a pathway for the registration of aldoxorubicin for KS with the FDA if the data are positive. The company expects to announce data from this Phase 2 clinical trial in Q2 2015.
News For CYTR From The Last 14 Days
Check below for free stories on CYTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
07:19 EDTCYTRCytRx presents aldoxorubicin Phase 2b trial data
CytRx announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin has been selected for oral presentation at the 2014 American Society for Clinical Oncology Annual Meeting. Aldoxorubicin is currently being studied in a pivotal, global Phase 3 clinical trial evaluating the efficacy and safety of aldoxorubicin as a second-line treatment for patients with STS under a Special Protocol Assessment with the FDA. CytRx is also conducting two Phase 2 clinical trials evaluating aldoxorubicin in patients with late-stage glioblastoma and HIV-related Kaposiís sarcoma.
April 11, 2014
10:35 EDTCYTRHigh option volume stocks: HZNP NI IPG CYTR SNV NBR
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use